Document:

exv10w1

Exhibit 10.1

THIRD AMENDMENT

TO THE AMENDED AND RESTATED

STRATEGIC ALLIANCE AGREEMENT

BY AND BETWEEN

PENWEST PHARMACEUTICALS CO.

AND

ENDO PHARMACEUTICALS INC.

This Third Amendment (this “Amendment”) to the Amended and Restated Strategic Alliance Agreement
dated as of April 2, 2002, and as amended by the Amendment Agreement dated January 7, 2007 and
further amended by the Second Amendment dated as of July 14, 2008 (the “Agreement”) is entered into
by and between Penwest Pharmaceuticals Co. (“Penwest”) and Endo Pharmaceuticals Inc. (“Endo”),
effective as of January 1, 2009.

Endo and Penwest agree as follows:

1. Section 1.23 of the Definitions Exhibit to the Agreement is amended by deleting Section 1.23 in
its entirety and inserting the following new Section 1.23 in its place:

1.23 “Formulated TIMERx Price” shall mean Penwest’s contract manufacturing cost (or, if
made internally, its variable costs plus directly allocable (a) fixed and (b) manufacturing
overhead costs relating to the manufacture or acquisition) of the Formulated TIMERx to be
provided to Endo or its Affiliates or sublicensees hereunder, as shall be determined and
adjusted no more often than annually plus the costs directly relating to the quality
control testing referred to in Section 7.2 hereof plus the allocable indirect costs
and fees referred to in the last two sentences of this Section 1.23; provided,
however, that any amounts paid or payable by Penwest for third-party royalties (or for
materials acquisition costs to the extent attributable to third-party intellectual
properties and essentially equivalent to royalties) which are the responsibility of Penwest
under Sections 9.5.1 or 9.5.2 hereof shall not be counted as part of the Formulated TIMERx
Price. Costs and fees related to and arising out of patent enforcement litigation ensuing
from a third party certifying against a Penwest Patent or a patent covering Penwest Product
Technology held by Penwest and listed in the FDA’s “Orange Book” may (to the extent not
reflected in the Certification Budget and the reconciliations under Section 3.7 hereof) be
included, at the option of Penwest and without prejudice to its other rights, as part of the
allocable indirect costs of the manufacture or acquisition of any Formulated TIMERx provided
for use in the Product; to the extent that such costs and fees are not reimbursed by Endo
to Penwest pursuant to Section 11.7. If any patent applications are filed or prosecuted by
Penwest on Penwest Product Technology, as provided in Section 6.2 hereof, the reasonable
costs thereof, and of the maintenance of any patents that issue
there-from, shall (to the
extent not reflected in the Certification Budget and the reconciliations under Section 3.7
hereof) be part of the allocable indirect costs of the manufacture or acquisition of any
Formulated TIMERx provided for use in the Product that would be disclosed in whole or in
part in such patent or patent application; to the extent that such costs and fees are not
reimbursed by Endo to Penwest pursuant to Section 6.2.

2. Section 6.2 of the Agreement is amended by inserting the following to the end of such Section
6.2:

The costs and fees incurred by or on behalf of Penwest relating to or in connection with any
patent applications filed or prosecuted by Penwest on Penwest Product Technology and the
maintenance of any patents that issue there-from in accordance with this Section 6.2 shall
be reimbursed to Penwest by Endo. Payments for such costs and fees incurred after December
31, 2008 shall be made to Penwest within thirty (30) days after presentation of each invoice
to Endo setting forth such costs and fees.

3. Endo shall reimburse Penwest in a single lump sum of $206,150 in full satisfaction of
un-recouped costs and fees incurred by or on behalf of Penwest through December 31, 2008 in
connection with the matters contemplated by Section 6.2 of the Agreement, which amount shall be
paid within ten (10) days of the date of this Amendment.

 

 

4. All other terms and conditions of the Agreement as previously amended are affirmed and remain in
full force and effect. The parties agree that all references in the Agreement to “this Agreement”
shall deem to include the provisions of this Amendment.

5. This Amendment shall be governed by, construed and enforced in accordance with, the laws of the
State of New York without regards to its conflict of laws rules.

* * *

     IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized representatives.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Endo Pharmaceuticals Inc.	 	 	 	Penwest Pharmaceuticals Co.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Nancy Wysenski	 	 	 	By:	 	/s/ Frank Muscolo	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Title:
	 	Chief Operating Officer
	 	 	 	 	 	Title:
	 	Controller & CAO	 	 
	 

	 	Date:
	 	March 27, 2009
	 	 	 	 	 	Date:
	 	March 31, 2009exv10w2

Exhibit 10.2

SEVERANCE AND SETTLEMENT AGREEMENT AND RELEASE

     This Severance and Settlement Agreement and Release (“Agreement”) is entered into by and
between Penwest Pharmaceuticals Co. (the “Company”) and Benjamin L. Palleiko (the “Employee”).

     WHEREAS, the parties wish to resolve amicably the Employee’s separation from the Company and
establish the terms of the Employee’s severance arrangement;

     NOW, THEREFORE, in consideration of the promises and conditions set forth herein, the
sufficiency of which is hereby acknowledged, the Company and the Employee agree as follows:

     1. Termination Date. The Employee’s date of termination from the Company is January
21, 2009 (the “Termination Date”). By executing this Agreement, the Employee hereby resigns,
effective as of the Termination Date, from his position as an officer of the Company.

     2. Consideration. In return for the Employee’s release and other promises set forth
in this Agreement, the Company agrees to provide the Employee with the following pay and other
benefits, referred to herein as “Severance Benefits”:

          (a) The Company agrees to provide severance pay to the Employee in the form of salary
continuation (at the rate of $11,576.92, less all applicable taxes and withholdings, per
regular Company pay period) for a period commencing on the Effective Date (as defined in Section 19
below) and ending on the date nine (9) months following the Effective Date (such period being
referred to as the “Severance Period”). The severance pay will be paid to the Employee in
accordance with the Company’s regular payroll practices, with the first payment to be made no
earlier than the Effective Date.

          (b) Upon the Effective Date, (i) the vesting of the options to purchase 45,500 shares of
common stock granted to the Employee on March 13, 2008 shall be accelerated such that as of the
Effective Date such options shall be deemed vested and shall be exercisable for a total of 11,375
shares of common stock and (ii) the vesting of the options to purchase 19,500 shares of common
stock granted to the Employee on June 11, 2008 shall be accelerated such that as of the Effective
Date such options shall be deemed vested and shall be exercisable
for a total of 4,875 shares of common stock..

 

 

          (c) If the Employee elects to continue group medical insurance pursuant to the federal COBRA
law, then, after the Effective Date, the Company will pay the Company portion of the Employee’s
health and dental insurance premiums for the Severance Period. Thereafter, the Employee may elect
to continue such coverage under COBRA for the remainder of the COBRA period, with the Employee
paying 100% of the cost of such coverage.

     3. Other Benefits. All employee benefits (other than health and dental insurance),
that the Employee received under Company-provided benefit plans, programs or practices, including
without limitation 401K and Employee Stock Purchase Plan (“ESPP”), terminated on the Termination
Date.

     4. 2008 Bonus. At the next payroll period following the Termination Date, the Company
will pay the Employee a bonus of $36,120 for the 2008 year.

     5. Release. The Employee hereby fully, forever, irrevocably and unconditionally
releases, remises and discharges the Company, and its parents, subsidiaries, affiliates,
successors, assigns, predecessors and present or former officers, directors, shareholders, agents,
employees, attorneys, fiduciaries, plan administrators, and representatives (collectively
“Releasees”) of and from any and all claims, charges, complaints, demands, actions, causes of
action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts,
agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and
expenses (including attorneys’ fees and costs), of every kind and nature, known or unknown, which
the Employee ever had or now has against any Releasees, including those arising out of the
Employee’s employment with or separation from the Company, through the date of the Employee’s
execution of this Agreement.

     Without limiting the foregoing, the Employee specifically releases and fully discharges the
Releasees of and from any and all claims, demands, causes of action, and rights, including but not
limited to: any alleged violation of federal, state or local laws prohibiting discrimination on the
basis of sex, race, age, disability, national origin, color, religion, veteran status, marital
status, sexual orientation, and specifically including all claims under the federal Age
Discrimination in Employment Act (ADEA), the Older Workers Benefit Protection Act, Title VII of the
Civil Rights Act of 1964, as amended, the Civil Rights Act of 1866, the Americans with Disabilities
Act of 1990 (ADA), and the Equal Pay Act of 1963, the Family and Medical Leave Act of 1993; the ERISA,
state family and

 

 

 medical leave laws and any federal or state wage payment laws, including the Fair
Labor Standards Act and the New York and Connecticut Wage Payment Laws, to the extent permitted by
law; any other federal, state (including New York and Connecticut) or local civil or human rights
laws; any public policy, contract, tort or common law obligation, including but not limited to
breach of express or implied contract or of an implied covenant of good faith and fair dealing,
negligent or intentional infliction of emotional distress; any claim of retaliation, any claim for
compensation, bonus, incentive pay, vacation pay, sick pay, expense reimbursement other than for
those expenses already submitted but not yet reimbursed, or other payments or benefits; and any
obligation for costs, fees or other expenses.

     Covenant Not to Sue. The Employee has not and will not commence any action, lawsuit,
or other legal proceeding against the Company or file any complaint with any federal, state, or
local agency against the Company relating to any claim arising before the Employee’s execution of
this Agreement; except that Employee may challenge in court the knowing and voluntary nature of
Employee’s waiver of any claim he may have, if any, under the Age Discrimination in Employment Act,
as amended by the Older Workers Benefit Protection Act, and that Employee may file a claim for
workers’ compensation benefits for injury or illness (excluding retaliation claims) and/or a claim
for unemployment compensation benefits. To the extent that Employee has pending any other action,
lawsuit, or legal proceeding against the Releasees, or any of them, relating to any claim arising
before the execution of this Agreement, Employee agrees that such action, lawsuit, or other legal
proceeding will be immediately withdrawn with prejudice. Nothing in this Agreement, however,
prevents the Employee from filing a charge or complaint, or participating in any investigation or
proceeding before a federal or state agency, but the Employee understands and acknowledges that he
will not be able to recover any monetary benefits in connection with any such claim, charge or
proceeding, and hereby expressly waives and disclaims his right to recover any relief, remedies, or
amounts, including costs and attorney’s fees.

     6. Return of Company Property. As further consideration for this Agreement, the
Company will release the cell phone number issued to the Employee and support the Employees efforts
to obtain the number through the vendor of the Employee’s choice. Except for the foregoing, the
Employee confirms that he will return to the Company, prior to the expiration of the revocation
period contemplated by Section 18(c) and the Effective Date, all Company property and equipment in
his possession or control, including, but not limited to, all keys, files, records
(and copies thereof), computer hardware, software and printers, wireless handheld devices,
cell phones, pagers, and

 

 

Company identification, and that he will leave intact all electronic
Company documents, including, but not limited to, those which he developed or helped develop during
his employment.

     7. Non-Admissions. The Employee understands and agrees that neither the negotiation,
undertaking nor signing of this Agreement constitutes or operates as an acknowledgement or
admission of liability, wrongdoing or violation of law on the part of the Company.

     8. No Claim for Compensation. The Employee acknowledges and represents that, except
as provided in Section 4 above, he has received all compensation, including all salary, wages,
vacation pay, bonuses, overtime pay, awards and all other forms of compensation that is, was, or
may be due to him and no additional compensation is owed to the Employee by the Company.

     9. No Claim for Benefits. The Employee acknowledges and represents that he received
all non-monetary benefits, including all leaves of absence, insurance coverage, and any other
benefits or rights to benefits to which he was entitled, that he was not and has not been denied
any benefits to which he is, was, or may be entitled, and that no additional benefits are owed to
the Employee by the Company.

     10. Validity. Should any provision of this Agreement be declared or be determined by
any court of competent jurisdiction to be illegal or invalid, excluding the release language, the
validity of the remaining parts, terms, or provisions shall not be affected thereby and said
illegal and invalid part, term or provision shall be deemed not to be a part of this Agreement. If
any portion of the release language were declared unenforceable for any reason, the Company’s
obligation to provide any remaining consideration under this Agreement shall cease.

     11. Confidentiality. To the extent permitted by law, the Employee understands and
agrees that the terms and contents of this Agreement, and the contents of the negotiations and
discussions resulting in this Agreement, shall be maintained as confidential by the Employee, and
may not be disclosed to any person other (a) than the Employee’s attorney(s) and/or tax advisor(s)
and/or immediate family only to the extent that said individuals first agree to maintain the
information as confidential, or (b) as required by law.

     12. Non-Disparagement. The Employee understands and agrees that as a condition for
payment to him of the Severance Benefits, he shall not make any false, disparaging or derogatory
statements in public or private to any person or entity, including without limitation, any media
outlet or any past, present or future employee, supplier,
customer or stockholder of the Company regarding the Company, any affiliated company, or any
of the Company’s past or present directors, officers, employees, agents, or representatives or
regarding the Company’s business affairs

 

 

or financial condition. The Company agrees that it shall
instruct the Company’s directors and officers, not to make any false, disparaging or derogatory
statements in public or private regarding the Employee to any person or entity, including without
limitation, any media outlet or any past, present, future or potential employer of the Employee.

     13. Post-Termination Confidentiality Obligation. The Employee acknowledges and
reaffirms his obligation to keep confidential and not to disclose or use any and all non-public
information concerning the Company which he acquired during the course of his employment with the
Company, including but not limited to business and marketing plans and strategy, financial
information, product information, technical information and personnel data. The Employee further
acknowledges and confirms his continuing obligations to the Company pursuant to the terms of the
Proprietary Information Agreement he signed on June 12, 2006 at the inception of his employment,
which agreement remains in full force and effect.

     14. Agreed Upon Statement. The Company agrees that the Employee will have the right
to review any public release or filing to be issued by the Company, regarding the Employee’s
employment or termination.

     15. Entire Agreement; Amendment. This Agreement contains and constitutes the entire
understanding and agreement between the parties hereto with respect to the subject matter hereof
and cancels all previous oral or written negotiations, agreements, commitments, and writings in
connection therewith. This Agreement may not be abandoned, supplemented, changed or modified in
any manner, orally or otherwise, except by an instrument in writing of concurrent or subsequent
date signed by the Employee and a duly authorized representative of the Company.

     16. Applicable Law; Successors. This Agreement shall be governed by the laws of the
State of Connecticut, without regard to its conflict of law provisions, and is binding upon and
shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors,
successors and administrators.

     17. Employment Termination Program. In accordance with the Age Discrimination in
Employment Act, as amended by the Older Workers Benefit Protection Act, the Company provides to the
Employee the information on the attached Schedule A.

     18. Employee Acknowledgments and Representations. The Employee understands,
acknowledges,
represents and agrees that:

          (a) the Employee has been given forty five (45) days to consider this Agreement and any
changes to the Agreement, whether material or otherwise, do not restart or otherwise affect the
original 45 day consideration period;

 

 

          (b) the Company has advised the Employee to consult with any attorney of his own choosing and
at his own cost prior to signing this Agreement;

          (c) the Employee may revoke this Agreement during a period of seven (7) days after his
execution of this Agreement by delivering the Employee’s written revocation within the seven (7)
day period to Susanne Donohue, 39 Old Ridgebury Road, Suite 11, Danbury, Ct 06810;

          (d) the Employee has read this Agreement and fully understands and agrees with all the terms
and conditions of this Agreement;

          (e) the Employee would not receive the Severance Benefits except for executing and abiding by
the terms of this Agreement;

          (f) by signing this Agreement, the Employee waives any right to bring or maintain a lawsuit or
make any other legal claims against any Releasees as described in this Agreement with respect to
any rights or claims, known or unknown, that arose prior to the Employee’s execution of this
Agreement;

          (g) the Employee freely and voluntarily assents to all of the terms and conditions of
this Agreement and signs his name of the Employee’s own free act.

     19. Effective Date. This Agreement shall not be effective or enforceable until the
eighth (8th) calendar day after the date of execution by the Employee if this Agreement
is not revoked by the Employee in accordance with Paragraph 19 (“Effective Date”).

     IN WITNESS WHEREOF, all parties have set their hand and seal to this Agreement as of the date
written below.

	 	 	 	 	 
	/s/ Benjamin L. Palleiko
 

Benjamin L. Palleiko

	 	 	 	January 28, 2009 
Date
	 
	 	 	 	 
	/s/ Jennifer L. Good
 

By Penwest Pharmaceuticals Co.

	 	 	 	January 30, 2009 
Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]